Table 4.
Pathologic features in isolated SMGN patients with and without NELL1 expression in glomerular immune deposits
| NELL1-positive | NELL1-negative | p value | |
|---|---|---|---|
| Immunofluorescence | |||
| IgG positivity, % | 57/58 (98.3) | 69/77 (89.6) | 0.077 |
| IgA positivity, % | 0/58 (0.0) | 4/77 (5.2) | 0.212 |
| IgM positivity, % | 38/58 (65.5) | 55/77 (71.4) | 0.463 |
| C3 positivity, % | 13/58 (22.4) | 10/77 (13.0) | 0.149 |
| C1q positivity, % | 0/58 (0.0) | 1/77 (1.3) | 1.000 |
| IgG Bowman capsule deposits, % | 5/58 (8.6) | 7/77 (9.1) | 0.924 |
| IgG subclass | |||
| IgG1, % | 19/20 (95.0) | 16/17 (94.1) | 1.000 |
| IgG2, % | 7/20 (35.0) | 4/17 (23.5) | 0.447 |
| IgG3, % | 2/20 (10.0) | 0/17 (0.0) | 0.489 |
| IgG4, % | 12/20 (60.0) | 12/17 (70.6) | 0.501 |
| Electron microscopy | |||
| No. diffuse (≥90%) foot process effacement, % | 11/53 (20.8) | 41/75 (54.7) | <0.001 |
| Stage of MN | |||
| Stage I, % | 20/54 (37.0) | 31/75 (41.3) | 0.622 |
| Stage II, % | 30/54 (55.6) | 26/75 (34.7) | 0.018 |
| Stage III, % | 2/54 (3.7) | 18/75 (24.0) | 0.002 |
| Stage IV, % | 2/54 (3.7) | 0/75 (0.0) | 0.173 |
| Mesangial EDD, % | 4/54 (7.4) | 11/75 (14.7) | 0.204 |
| Subendothelial EDD, % | 0/54 (0.0) | 2/74 (2.7) | 0.508 |